Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Venus Remedies Ltd (VENUSREM)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 526953 NSE: VENUSREM Pharmaceuticals & Drugs | Small Cap | Venus Remedies Share Price
₹1,737.05 80.05 (4.83%)
As on 13-Aug'26 16:59
Venus Remedies Ltd (VENUSREM)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 526953 NSE: VENUSREM Pharmaceuticals & Drugs | Small Cap | Venus Remedies Share Price
₹1,737.05 80.05 (4.83%)
As on 13-Aug'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹2,322 Cr.
Current Price
₹1,737.1
52-Week Low / High
₹424 / 2,043
TTM EPS
₹86.9
TTM Sales
₹811 Cr.
Book Value per Share
₹513.7
P/E Ratio
19.99
Higher than its 5-year historical median
Industry PE
53.4
Price to Book (P/B)
3.38
Higher than its 5-year historical median
Price to Sales (P/S)
2.86
Higher than its 5-year historical median
EV/EBITDA
12.89
Higher than its 5-year historical median
Dividend Yield
0.58%
Profitability Efficiency
Return on Equity (ROE)
16.79%
Outperforms industry median
Return on Capital Employed (ROCE)
21.88%
Outperforms industry median
Return on Assets (ROA)
13.10%
Operating Profit Margin
19.1%
Net Profit Margin
13.36%
Gross Profit Margin
20.8%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
17.88%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
114.88%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
126.86%
Asset Quality
Promoter Holding
41.76%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹673 Cr.
Equity
₹13.4 Cr.
Face Value
₹10
All Time Low / High
₹1.00 / 2043.15
Check Before You Invest
Quality
Somewhat GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Semi Strong
Is Venus Remedies Ltd a good quality company?
Venus Remedies Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Venus Remedies Ltd performance compare with that of its Peers?
Revenue growth of Venus Remedies Ltd vs industry peers?
Venus Remedies Ltd revenue CAGR is 7.02%, compared to the industry median CAGR of 5.68%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Venus Remedies Ltd?
Promoters hold 41.76% of the Venus Remedies Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Venus Remedies Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 34.9% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Venus Remedies Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 2% | 1.2% | -0.7% | 0.9% | 12.4% | 7.9% | 7.7% | 8.7% | 13.2% | 21.9% | - |
| Value Creation Index ⓘ | -0.9 | -0.9 | -1.1 | -0.9 | -0.1 | -0.4 | -0.5 | -0.4 | -0.1 | 0.6 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 400 | 372 | 322 | 339 | 548 | 600 | 556 | 601 | 653 | 770 | 811 |
| Sales YoY Gr. | - | -6.9% | -13.6% | 5.4% | 61.5% | 9.5% | -7.4% | 8.3% | 8.6% | 17.9% | - |
| Adj EPS ⓘ | -15 | -24.9 | -20.1 | -4.6 | 33.1 | 27.1 | 16 | 18.2 | 28.7 | 76.9 | 86.9 |
| YoY Gr. | - | NA | NA | NA | NA | -18% | -40.8% | 13.5% | 57.8% | 167.9% | - |
| BVPS (₹) ⓘ | 314.9 | 293.2 | 269.4 | 262 | 313.2 | 329.5 | 344.4 | 364.7 | 419.7 | 496.6 | 513.7 |
| Adj Net Profit ⓘ | -18.5 | -30.8 | -24.8 | -5.7 | 40.8 | 36.2 | 21.4 | 24.3 | 38.4 | 103 | 116 |
| Cash Flow from Ops. ⓘ | 58.9 | 31.2 | 45.3 | 77.6 | 132 | 41.1 | 36.6 | 37.3 | 86.4 | 156 | - |
| Debt/CF from Ops. ⓘ | 5.3 | 9.8 | 6.6 | 2.8 | 0.4 | 1 | 1.2 | 1.1 | 0 | 0 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 7.5% | 7% | 11.5% | 17.9% | ||||
| Adj EPS ⓘ | NA | 18.4% | 68.6% | 167.9% | ||||
| BVPSⓘ | 5.2% | 9.7% | 13% | 18.3% | ||||
| Share Price | 35.1% | 28.1% | 86.8% | 260.7% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -4.5 | -8.2 | -7.1 | -1.7 | 11.3 | 8.6 | 4.8 | 5.1 | 7.3 | 16.8 | 17.2 |
| Op. Profit Mgn % ⓘ | 12.7 | 10.6 | 10.1 | 12 | 9.8 | 10.4 | 10.8 | 9.9 | 10.5 | 19.1 | 20.5 |
| Net Profit Mgn % ⓘ | -4.6 | -8.3 | -7.7 | -1.7 | 7.5 | 6 | 3.9 | 4 | 5.9 | 13.4 | 14.3 |
| Debt to Equity ⓘ | 0.8 | 0.9 | 0.9 | 0.7 | 0.1 | 0.1 | 0.1 | 0.1 | 0 | 0 | - |
| Working Cap Days ⓘ | 270 | 285 | 337 | 338 | 188 | 152 | 180 | 177 | 167 | 142 | 91 |
| Cash Conv. Cycle ⓘ | 152 | 153 | 170 | 147 | 70 | 56 | 83 | 87 | 71 | 46 | 60 |
Valuation of Venus Remedies - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 400 | 372 | 322 | 339 | 548 | 600 | 556 | 601 | 653 | 770 |
| Operating Expenses ⓘ + | 349 | 333 | 289 | 299 | 494 | 538 | 495 | 542 | 584 | 622 |
| Operating Profit ⓘ | 51 | 39 | 33 | 41 | 54 | 62 | 60 | 60 | 69 | 147 |
| Operating Profit Margin (%) | 12.7% | 10.6% | 10.1% | 12.0% | 9.8% | 10.3% | 10.8% | 9.9% | 10.5% | 19.1% |
| Other Income ⓘ + | 4 | 2 | 6 | 5 | 20 | 8 | 10 | 12 | 16 | 13 |
| Interest ⓘ | 36 | 36 | 25 | 13 | 13 | 0 | 0 | 0 | 0 | 0 |
| Depreciation ⓘ | 40 | 34 | 34 | 32 | 35 | 34 | 32 | 26 | 23 | 26 |
| Profit Before Tax ⓘ | -22 | -28 | -30 | -8 | 49 | 36 | 38 | 45 | 72 | 134 |
| Tax ⓘ | -5 | 3 | -1 | 2 | -13 | -4 | 11 | 16 | 27 | 31 |
| Profit After Tax | -17 | -31 | -29 | -10 | 62 | 41 | 27 | 28 | 45 | 103 |
| PAT Margin (%) | -4.3% | -8.2% | -8.9% | -3.0% | 11.3% | 6.8% | 4.8% | 4.7% | 6.9% | 13.4% |
| Adjusted EPS (₹) | -13.8 | -24.9 | -23.2 | -8.1 | 50.0 | 30.5 | 19.9 | 21.3 | 33.9 | 76.9 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 13% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 389 | 362 | 333 | 323 | 387 | 440 | 460 | 488 | 561 | 664 | |
| Debt + | 281 | 259 | 229 | 158 | 51 | 43 | 42 | 41 | 2 | 0 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 30 | 29 | 36 | 37 | 71 | 50 | 51 | 53 | 92 | 113 | |
| Others Liabilities ⓘ | 66 | 101 | 135 | 126 | 47 | 46 | 48 | 45 | 61 | 76 | |
| Total Liabilities ⓘ | 765 | 751 | 733 | 644 | 556 | 579 | 601 | 627 | 716 | 854 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 406 | 389 | 364 | 289 | 262 | 241 | 216 | 219 | 229 | 232 | |
| CWIP ⓘ | 66 | 65 | 65 | 25 | 25 | 25 | 26 | 21 | 26 | 51 | |
| Investments ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 19 | 84 | 238 | |
| Inventories | 141 | 138 | 143 | 141 | 120 | 126 | 120 | 122 | 100 | 129 | |
| Trade Receivables | 47 | 47 | 38 | 31 | 32 | 39 | 77 | 80 | 112 | 103 | |
| Cash Equivalents | 4 | 4 | 3 | 2 | 31 | 50 | 54 | 68 | 80 | 30 | |
| Others Assets ⓘ | 101 | 107 | 120 | 156 | 86 | 98 | 88 | 98 | 83 | 71 | |
| Total Assets ⓘ | 765 | 751 | 733 | 644 | 556 | 579 | 601 | 627 | 716 | 854 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 59 | 31 | 45 | 78 | 132 | 41 | 37 | 37 | 86 | 156 |
| Cash Flow From Investing Activity ⓘ + | -18 | -11 | -11 | -5 | 56 | -17 | -51 | -7 | -76 | -182 |
| Cash Flow From Financing Activity ⓘ + | -44 | -39 | -35 | -73 | -162 | -9 | -1 | -1 | -1 | -3 |
| Net Cash Flow ⓘ | -4 | -20 | -1 | -0 | 26 | 15 | -15 | 29 | 9 | -29 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -4.13 | -8.18 | -8.23 | -3.05 | 17.4 | 9.85 | 5.9 | 6.01 | 8.64 | 16.79 |
| ROCE (%) | 2 | 1.17 | -0.67 | 0.9 | 12.37 | 7.89 | 7.72 | 8.67 | 13.17 | 21.88 |
| Asset Turnover Ratio | 0.5 | 0.49 | 0.43 | 0.49 | 0.91 | 1.06 | 0.94 | 0.98 | 0.97 | 0.98 |
| PAT to CFO Conversion(x) | N/A | N/A | N/A | N/A | 2.13 | 1 | 1.37 | 1.32 | 1.91 | 1.51 |
| Working Capital Days | ||||||||||
| Receivable Days | 49.70 | 46.30 | 48.40 | 37 | 20.90 | 21.50 | 37.90 | 47.70 | 53.90 | 51.10 |
| Inventory Days | 129.50 | 136.60 | 159.30 | 152.70 | 86.90 | 74.70 | 80.70 | 73.30 | 62.10 | 54.50 |
| Payable Days | 44.10 | 52.60 | 65.50 | 76.10 | 57.90 | 57.30 | 55.70 | 53.50 | 69.90 | 96.80 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Venus Remedies Ltd FAQs
The current trading price of Venus Remedies on 13-Aug-2026 16:59 is ₹1,737.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Aug-2026 the market cap of Venus Remedies stood at ₹2,321.9 Cr
The latest P/E ratio of Venus Remedies as of 12-Aug-2026 is 20.52.
The latest P/B ratio of Venus Remedies as of 12-Aug-2026 is 3.25.
The 52-week high of Venus Remedies is ₹2,043.2 and the 52-week low is ₹423.7.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Venus Remedies is ₹810 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Venus Remedies Ltd is a average quality company.
The key valuation ratios of Venus Remedies Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Venus Remedies Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
About Venus Remedies Ltd
Venus Remedies incorporated in 1989, is a pharmaceutical manufacturing company. The company provides formulations in area of anti-biotics and oncological therapeutics.
Company has two manufacturing facilities located in India and Germany. Company manufactures Oncological and Cefelosporine Injectable products.
Its manufacturing facility located in India has received ISO 9001, ISO, 14001 and OHSAS 18001 for quality management. Its Germany facility follows EU-GMP norms.
Presently, the company has successfully made its presence in the markets of Philippines, Thailand, Malaysia, Cambodia, Burma, Vietnam, Sri Lanka, Pakistan, Bangladesh, Nepal, Uganda, Kenya, Botswana, Zimbabwe, Sudan, Mauritius, Yemen, Iraq, Russia, Belarus, Ukraine, Costa Rica, Venezuela, Guatemala, Peru, Colombia, Ecuador, Syria, Yeman, Togo, Saudi Arbia and Iraq.
Company has entered into strategic alliances with various pharmaceutical companies to launch its R&D based specialty products. It has tie-ups with companies namely IPCA Laboratories, Elder Pharmaceuticals, Shreya Lifesciences, Cadila Healthcare, Glenmark Pharmaceuticals, Marksans Pharma, Indoco Remedies, Karle Health Sciences, Lupin and Jagsonpal Pharmaceuticals.
Company also conducts in-house research and development activities that focuses Formulation Development, NDDS (Novel Drug Delivery System), new formulations of off patented chemicals and analytical and chemical research.
Products
The company is engaged in manufacturing products catering various segments such as Oncology, Cephalosporins, Carbapenems and Other Specialties, Intravenous Products, Vials/Lyophilized Injectables, Pre-Filled Syringes, Hormones, Ampoules and Biological Products.
Milestone/ Awards
2009
Venus Remedies - Product Patent for "TOBRACEF" granted in South Africa.
Venus Bags Another Product Patent from South Africa for POTENTOX.
2010
Venus Remedies receives GMP Certification from Botswana".
Venus Remedies ties up with IMTECH and Panjab Univ to develop Typhoid detection kits.
The Company has received approval from the Reserve Bank of India for rollover of FCCB USD 5mn, with YTM @4% with maturity till February 15, 2015.
Venus Remedies research Blockbuster "Sulbactomax" gets European Union Patent"
2011
Venus Remedies Ltd wins Gold Medal for TROIS under DST - Lockheed Martin India Innovation Growth Program 2011.
Venus launches its patented research product ACHNIL†in India.
Venus Remedies wins ""India Manufacturing Excellence Award 2011.
2012
Venus Remedies introduces "Ready-to-Use"" Single Vial Taxedol in India
Venus Remedies Limited introduced TROIS that is a research based, patent protected topical nano-emulsion product in India
The Company has won Manufacturing Award for its world class manufacturing and operational excellence at the "Industry 2.0 Manufacturing Innovation Conclave 2012.
Venus wins Patent award in Silver Category.
You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
